Blume Capital Management, Inc. Exelixis, Inc. Transaction History

Blume Capital Management, Inc.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 02, 2024	SELL	$20.17 - $23.93 $8,068 - $9,572	-400 Reduced 50.0%	400 $9,000
Q3 2023 May 01, 2024	SELL	$19.04 - $22.74 $15,232 - $18,192	-800 Reduced 50.0%	800 $17,000
Q3 2023 Nov 03, 2023	SELL	$19.04 - $22.74 $15,232 - $18,192	-800 Reduced 50.0%	800 $17,000
Q1 2023 May 01, 2024	BUY	$16.3 - $19.41 $13,040 - $15,528	800 Added 100.0%	1,600 $31,000
Q2 2022 Aug 11, 2022	SELL	$17.44 - $23.16 $8,929 - $11,857	-512 Reduced 24.24%	1,600 $33,000
Q2 2021 Aug 10, 2021	SELL	$17.95 - $25.56 $28,720 - $40,896	-1,600 Reduced 43.1%	2,112 $38,000
Q4 2020 Feb 09, 2021	BUY	$18.39 - $24.8 $9,415 - $12,697	512 Added 16.0%	3,712 $75,000
Q2 2020 Aug 06, 2020	SELL	$16.46 - $27.42 $32,920 - $54,840	-2,000 Reduced 38.46%	3,200 $76,000
Q1 2020 May 07, 2020	SELL	$14.46 - $21.8 $14,460 - $21,800	-1,000 Reduced 16.13%	5,200 $89,000
Q1 2019 May 06, 2019	SELL	$19.6 - $24.76 $30,282 - $38,254	-1,545 Reduced 19.95%	6,200 $148,000
Q4 2018 Feb 05, 2019	BUY	$13.65 - $21.8 $105,719 - $168,841	7,745 New	7,745 $152,000

503

244M

2.54M

2.29M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $11.6B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Blume Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Blume Capital Management, Inc. with notifications on news.